Locations:
Min Investment:
Max Investment:
Target Investment:
Total Funding: $28M
Total Funding: $81M
Total Funding: $110M
Total Funding: $150M
Total Funding: $100M
Total Funding: $46M
Total Funding: $290M
Total Funding: $19M
Total Funding: $110M
Total Funding: $41M
2007
2017
2014 - 2017
2010 - 2014
2007 - 2010
2024
2024
2021
2021
2021
2021
2020
2021
VectorY develops innovative vectorized antibody gene therapies
2020 - 2021
VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics such as vectorized antibodies for both CNS and somatic disorders, with a special focus on muscle diseases.
2020 - 2023
2020 - 2023
Oxitope Pharma was merged with Arxx Therapeutics into Calluna Pharma
2017 - 2023
2017 - 2023
EnGene (Nasdaq: ENGN) develops non-viral gene therapies targeting mucosal tissues. Lead program is in pivotal clinical studies in NMIBC
2020 - 2023
2020 - 2023
Inversago develops peripherally acting CB1 inhibitors for treatment of metabolic and inflammatory diseases. Inversago was acquired by Novo Nordisk
2018 - 2023
2018 - 2023
Escalier develops novel therapeutics to treat autoimmune diseases
2018 - 2020
2018 - 2020
Inflazome was acquired by Roche